Short Interest in Novogen Limited (NASDAQ:KZIA) Expands By 39.8%

Novogen Limited (NASDAQ:KZIA) was the target of a large growth in short interest in February. As of February 27th, there was short interest totaling 68,201 shares, a growth of 39.8% from the February 12th total of 48,796 shares. Currently, 4.2% of the shares of the stock are short sold. Based on an average trading volume of 234,547 shares, the short-interest ratio is currently 0.3 days. Based on an average trading volume of 234,547 shares, the short-interest ratio is currently 0.3 days. Currently, 4.2% of the shares of the stock are short sold.

Novogen Stock Performance

Shares of KZIA opened at $7.49 on Monday. The business has a fifty day moving average of $6.85 and a 200 day moving average of $7.78. Novogen has a 52-week low of $2.86 and a 52-week high of $17.40.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on KZIA shares. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Novogen in a report on Wednesday, January 28th. Wall Street Zen downgraded shares of Novogen from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $19.00.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.